Stay updated on Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page.

Latest updates to the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedA minor revision tag was updated from v3.4.1 to v3.4.2, with no substantive changes to study content or page elements. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1. This is a minor metadata update that does not affect study details or user interactions; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedThe page shows minor UI and metadata updates: a new 'Show glossary' option appears, capitalization variations for 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' are adjusted, and the revision tag updated to v3.4.0 from v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check41 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4 on the page, indicating a technical update with no changes to study content or eligibility criteria. No study data or interactions were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedLocations section updated to include California. The California Locations header was removed, the HHS Vulnerability Disclosure link was removed from the footer, and the revision tag updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check91 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2. No substantive study information appears to be affected.SummaryDifference0.1%

Stay in the know with updates to Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page.